ABT vs BDX
Abbott Laboratories vs Becton Dickinson — AI-powered side-by-side comparison
ABT
Abbott Laboratories
66
Buy
VS
BDX
Becton Dickinson
50
Watch
| Metric | ABT | BDX |
|---|
| AI Score |
66
|
50
|
| Price |
$116.70
|
$190.62
|
| P/E Ratio |
37.51×
|
57.45×
|
| ROE |
12.5%
|
6.6%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
56.8%
|
46.1%
|
| Debt / Equity |
0.64×
|
0.69×
|
| Dividend Yield |
2.1%
|
2.0%
|
| RSI (14) |
84.7
|
77.5
|
| Beta |
0.581
|
0.258
|
| Expected Upside |
+0.1%
|
+2.4%
|
AI Committee View
Current Innellis committee reasoning for ABT versus BDX.
ABT leads by 16 points.
ABT scores 66/100 (Buy) versus BDX at 50/100 (Watch).
ABT Committee View
50% agreement
4 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- MACD histogram positive -- bullish momentum — Technical
- Weekly trend (sideways) confirms the daily trend -- multi-timeframe agreement — Technical
Bear Case
- RSI at 85 is in overbought territory — Technical
- Price trading above the upper Bollinger Band -- stretched — Technical
- Weekly RSI at 83 -- overbought on the larger timeframe too — Technical
BDX Committee View
33% agreement
6 analysts
The committee is genuinely divided. Macro Analyst sees a compelling case. Value Analyst remains cautious — p/e of 53.2 is expensive by classic value standards. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- 3 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- P/E of 53.2 is expensive by classic value standards — Value
- ROE of only 3.8% -- cheap may mean cheap for a reason — Value
- Revenue declining -2.6% YoY -- this is not a growth story right now — Growth